Pharmacology and Nursing Care: Coagulation Modifier Drugs

Overview of Coagulation Modifier Drugs

• Categories of Drugs Affecting Perfusion:     * Anticoagulants     * Antiplatelets     * Thrombolytics (also known as Fibrinolytics)
• Significance in Nursing Practice:     * These medications are common across acute, chronic, and perioperative care settings.     * Small changes in dosing or monitoring can lead to large impacts on patient outcomes.     * Nurses are central to maintaining the delicate balance between bleeding and clotting.     * These are considered high-alert medications that require vigilance and strong assessment skills.

Nursing Roles and Responsibilities

• Core Responsibilities:     * Safe administration of medications.     * Monitoring of laboratory values, trends, and clinical symptoms.     * Recognition of early signs indicating either bleeding or clotting.
• Monitoring and Assessment:     * Evaluation of coagulation labs: PT/INR, aPTT, and CBC based on the specific ordered therapy.     * Assessment for both hidden and visible bleeding.     * Trending vital signs to detect subtle physiological changes.     * Monitoring the effectiveness of the drug and symptom relief within the clinical context.
• Safety Systems and Safeguards:     * Utilization of standardized order sets and protocols.     * Involvement of pharmacy in medication reconciliation.     * Implementation of double-checks for high-alert infusions.     * Clear communication during care transitions.
• Emergency Preparedness:     * Rapid recognition of severe bleeding.     * Knowledge of the location and protocols for reversal agents.     * Early activation of rapid response teams and escalation.     * Performance of supportive measures according to institutional guidelines.

Patient Education and Lifestyle Considerations

• General Education Overview:     * Stress the importance of adherence; patients must not miss doses.     * Teach patients to report signs of excessive bleeding immediately.     * Review lifestyle risks, including falls, injury risk, and over-the-counter (OTC) drug interactions.     * Reinforce the need for consistent follow-up and laboratory appointments.
• Home Care Specifics:     * Preference for Direct Oral Anticoagulants (DOACs) due to ease of use and lack of required lab monitoring.     * Warfarin requires frequent INR checks and consistent dietary habits.     * Focus on bleeding precautions: use of a soft toothbrush and electric razors.     * Fall prevention strategies and emergency responses for uncontrolled bleeding.

Fundamentals of Hemostasis

• Definition: Hemostasis is the general term for any process that stops bleeding.
• Three Main Steps of Hemostasis:     1. Vascular spasm.     2. Platelet plug formation.     3. Coagulation.
• Coagulation Process:     * Physiologic clotting of blood.     * Involves the "clotting cascade," a series of reactions leading to a "stable" blood clot.     * Clotting factors (proteins in the blood) are activated in a cascade resulting in Fibrin, the clot-forming substance.
• The Three Pathways:     * Intrinsic Pathway: Activated by trauma inside the vascular system. Triggered by platelets, exposed endothelium, chemicals, or collagen. Involves factors XII, XI, and VIII.     * Extrinsic Pathway: Activated by external trauma causing blood to escape the vascular system. Involves factor VII and tissue factor (TF).     * Common Pathway: The point where both pathways converge. Involves factors X, V, II (prothrombin), I (fibrinogen), and XIII.
• The Role of the Liver:     * Responsible for the synthesis of clotting factors.     * Produces Vitamin K-dependent factors.     * Produces anticoagulants and fibrinolytic proteins.     * Liver disease significantly impacts these processes.

Clotting and Thromboembolic Disorders

• Thrombogenesis (Thrombosis):     * The formation of blood clots.     * It is a normal defense to prevent blood loss but becomes pathologic when it causes vascular obstruction.     * An embolus is a section of a thrombus that breaks off and travels through the bloodstream.
• Atherosclerosis:     * Accumulation of lipid-filled macrophages (foam cells) on the inner lining of arteries.     * Can affect any organ or tissue.     * Commonly involves arteries supplying the heart (MI risk), brain (stroke risk), and legs (DVT risk).
• Venous Thrombosis:     * Associated with venous stasis.     * Thrombi are less cohesive than arterial thrombi.     * Emboli are more likely to detach and travel.     * Leads to Deep Vein Thrombosis (DVT) and embolization.
• Specific Disorders:     * Hemophilia: A rare genetic disorder where natural coagulation factors are limited or absent. Patients can bleed to death without factor replacement. Types involve Factor VII deficiency or Factor VIII/IX deficiency.     * Von Willebrand Disease: The most common inherited bleeding disorder (autosomal dominant). Caused by decreased or dysfunctional von Willebrand factor VIII, leading to reduced platelet adhesion.     * Vitamin K Deficiency: Caused by insufficient absorption. Affects all pathways because Vitamin K is a required cofactor for factors II, VII, IX, and X.
• Concept Check (True/False):     * Question: Thrombogenesis involves the presence of a blood clot.     * Answer: True.

Anticoagulant Drugs: General Principles

• Mechanism: Prevents new clot formation or the extension of existing clots. They do not dissolve existing clots.
• Goals: Improve blood flow in tissues around a clot and prevent ischemic damage beyond the clot.
• Indications:     * Atrial Fibrillation (Afib).     * Venous Thromboembolism (VTE) including DVT and Pulmonary Embolism (PE).     * Acute Coronary Syndrome (ACS).     * Post-operative prophylaxis.
• Main Adverse Effect: Bleeding.
• Contraindications:     * Drug allergy.     * Acute bleeding process or high risk of bleeding.     * Warfarin is strongly contraindicated in pregnancy.     * LMWHs are contraindicated in patients with indwelling epidural catheters (risk of epidural hematoma).
• Interactions:     * Enzyme inhibition of metabolism.     * Displacement from protein-binding sites.     * Decreased Vitamin K absorption from gut flora changes.     * Rule: Always question an order if two anticoagulants are ordered, EXCEPT for "bridge therapy" (e.g., heparin/enoxaparin and oral warfarin).

Heparin and Low-Molecular-Weight Heparins (LMWHs)

• Unfractionated Heparin (UFH):     * Obtained from pig lungs or intestinal mucosa.     * Inhibits clotting factors IIa (thrombin) and Xa.     * Concentrations range from $10$ to $40,000\text{ units/mL}$.     * Prophylaxis DVT: $5000\text{ units}$ subcutaneously two or three times daily. (No aPTT monitoring needed for prophylaxis).     * Therapeutic Treatment: Continuous IV infusion. Requires aPTT measurement, usually every $6\text{ hours}$ until therapeutic.     * Nursing Implications: IV doses must be double-checked by another nurse. Do not give SQ doses IM. Rotate sites in deep subcutaneous fat. Avoid injection within $2\text{ inches}$ of the umbilicus, incisions, wounds, scars, or stomas. Do not aspirate or massage (prevents hematoma).     * Antidote: Protamine sulfate. $1\text{ mg}$ of protamine reverses $100\text{ units}$ of heparin.
• Enoxaparin (Lovenox) and Dalteparin (Fragmin):     * LMWHs with a greater affinity for factor Xa than IIa.     * Higher bioavailability and longer half-life than UFH.     * Lab monitoring (aPTT) is not necessary.     * Administration: Subcutaneous in the abdomen. Rotate sites. Enoxaparin comes in pre-filled syringes; do not expel the air bubble.
• Heparin-Induced Thrombocytopenia (HIT):     * Type I: Gradual reduction in platelets; heparin can usually continue.     * Type II: Acute fall in platelets (>50\% \text{ reduction} from baseline); heparin must be discontinued.

Direct Thrombin Inhibitors (DTIs)

• Mechanism: Inhibit factor IIa (thrombin).
• Agents:     * Natural: Human antithrombin III (Thrombate).     * Synthetic (IV): Lepirudin (Refludan), Argatroban, Bivalirudin (Angiomax).     * Synthetic (Oral): Dabigatran (Pradaxa).
• Argatroban: Used for active HIT and percutaneous coronary interventions in HIT-risk patients. Only given IV.
• Dabigatran (Pradaxa):     * First oral DTI approved for stroke/thrombosis prevention in non-valvular Afib.     * A prodrug activated in the liver.     * Reversibly binds to free and clot-bound thrombin.     * Dose is dependent on renal function.     * No coagulation monitoring required.     * Antidote: Idarucizumab (Praxbind).

Warfarin (Coumadin)

• Mechanism: Inhibits Vitamin K-dependent clotting factors.
• Monitoring: Precise monitoring of Prothrombin Time (PT) and International Normalized Ratio (INR).     * Normal INR (no warfarin): $1.0$.     * Therapeutic INR: Ranges from $2$ to $3.5$ based on indication (e.g., Afib, prosthetic heart valve).
• Pharmacokinetics: Full therapeutic effect takes several days. May be started as bridge therapy while the patient is still on heparin.
• Genetics: Variations in CYP2CP and VKORC1 genes affect response.
• Antidote: Vitamin K1 (phytonadione).     * Liver takes $36-42\text{ hours}$ to resynthesize factors naturally after stopping warfarin.     * High dose ($10\text{ mg}$) IV Vitamin K reverses anticoagulation within $6\text{ hours}$.
• Dietary and Herbal Interactions:     * Herbal products increasing bleeding: Capsicum pepper, Garlic, Ginger, Ginkgo, St. John’s wort, Feverfew, Dong quai.     * Food: Maintain consistent intake of dark leafy greens and tomatoes (high in Vitamin K).

Factor Xa Inhibitors

• Injectable: Fondaparinux (Arixtra).
• Direct Oral Anticoagulants (DOACs):     * Rivaroxaban (Xarelto).     * Apixaban (Eliquis).     * Edoxaban (Savaysa).     * Betrixaban (Bevyxxa).
• Rivaroxaban (Xarelto):     * First oral factor Xa inhibitor.     * Used for stroke prevention in Afib, post-op ortho prophylaxis, and DVT/PE treatment.     * Adverse reactions: Peripheral edema, dizziness, headache, bruising, diarrhea, hematuria.

Antiplatelet Drugs

• Mechanism: Inhibit platelet aggregation and adhesion to prevent platelet plugs.
• List of Agents:     * Aspirin.     * Clopidogrel (Plavix) - Most widely used ADP inhibitor (oral).     * Prasugrel (Effient), Ticagrelor (Brilinta).     * Cilostazol (Pletal), Dipyridamole (Persantine).     * Treprostinil (Remodulin).     * Abciximab (ReoPro), Eptifibatide (Integrilin), Tirofiban (Aggrastat).     * Anagrelide (Agrylin), Vorapaxar (Zontivity).
• Aspirin specific:     * Contraindicated for children/teenagers with flu-like symptoms due to risk of Reye's syndrome.     * Aggrenox is a combination of aspirin and dipyridamole.

Thrombolytic (Fibrinolytic) Agents

• Mechanism: Dissolve existing thrombi by stimulating the conversion of plasminogen to plasmin (the enzyme that digests fibrin).
• Agents:     * Older: Streptokinase, Urokinase.     * Current (t-PA): Alteplase (Activase, Cathflo Activase), Tenecteplase (TNKase).
• Alteplase (Activase):     * Fibrin-specific; does not cause a systemic lytic state.     * Very short half-life of $5\text{ minutes}$.     * Indications: acute MI, stroke, and small doses for flushing clogged IV/arterial lines.
• Administration Constraints:     * Performed only by experienced personnel in ICU or diagnostic settings with cardiac monitoring.     * Requires baseline labs (INR, aPTT, platelets, fibrinogen).     * Strict inclusion/exclusion criteria for time-sensitive emergencies.
• Nursing Implications: Monitor IV sites for bleeding. Observe for internal bleeding signs: decreased BP, restlessness, increased pulse.

Antifibrinolytic and Hemostatic Drugs

• Mechanism: Prevent the lysis of fibrin; promote blood coagulation.
• Indications: Hyperfibrinolysis, surgical complications, Hemophilia, or Von Willebrand’s disease.
• Specific Drugs:     * Aminocaproic acid (Amicar): Synthetic; controls bleeding from surgery or overactive fibrinolytic system (Oral/Parenteral).     * Tranexamic acid (Cyklokapron): Prevents plasminogen displacement from fibrin; used IV prior to surgery. Rapid IV injection can cause hypotension.     * Desmopressin (DDAVP): Synthetic polypeptide similar to vasopressin. Oral/Injectable for Hemophilia/Diabetes Insipidus; nasal spray for nocturnal enuresis.
• Adverse Effects: Uncommon but can include thrombotic events, dysrhythmias, orthostatic hypotension, and GI distress.

Monitoring and Diagnostic Tests

• aPTT (activated Partial Thromboplastin Time):     * Measures intrinsic and common pathways.     * Normal: $30-40\text{ seconds}$.     * PTT (non-activated) normal: $60-70\text{ seconds}$.
• PT (Prothrombin Time):     * Measures extrinsic and common pathways.     * Normal: $11.0-12.5\text{ seconds}$.
• INR (International Normalized Ratio):     * DVT Prophylaxis: $1.5-2.0$.     * DVT Treatment: $2.0-3.0$.     * Atrial Fibrillation: $3.0-4.0$.
• Platelets:     * Adult/Child: $150,000-400,000\text{/mm}^3$.     * Premature infants: $100,000-300,000\text{/mm}^3$.     * Newborns: $150,000-300,000\text{/mm}^3$.     * Infants: $200,000-475,000\text{/mm}^3$.
• Fibrinogen:     * Normal: $200-400\text{ mg/dL}$.     * Newborn: $125-300\text{ mg/dL}$.
• D-Dimer:     * Measures protein fragments from dissolved clots.     * Normal: <500\text{ ng/mL} or <0.5\text{ \mu g/mL}.

Use in Special Populations

• Children: DOACs (rivaroxaban, dabigatran) are now approved for pediatric VTE. LMWH remains preferred due to predictable safety.
• Older Adults: DOACs preferred over warfarin due to lower intracranial hemorrhage risk. However, dabigatran/rivaroxaban increase GI bleeding risk.
• Renal Impairment:     * UFH is preferred as it is short-acting and reversible.     * Apixaban is safest for eGFR <15\text{ mL/min} or dialysis.     * Avoid Dabigatran and Rivaroxaban in advanced Chronic Kidney Disease (CKD).
• Hepatic Impairment: Cirrhosis increases both bleeding and thrombosis risks. LMWH and Warfarin are traditional first-line; requires close monitoring of liver function and platelets.
• Herbal and Dietary Supplements:     * Increase bleeding: Garlic, ginger, ginkgo, turmeric, fish oil, feverfew.     * Increase Warfarin INR: Dong quai, red yeast rice, Vitamin E.     * Decrease Warfarin INR: St. John’s wort, ginseng, CoQ10, Vitamin K-rich foods.